120 related articles for article (PubMed ID: 9013191)
1. N-(Hydroxymethyl) melamines.
Coley HM
Gen Pharmacol; 1997 Feb; 28(2):177-82. PubMed ID: 9013191
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol.
Coley HM; Jarman M; Brooks N; Kubota T; Goddard PM; Jones M; Lee N; Owens MD; Halbert GW; Judson IR
Int J Cancer; 1996 Nov; 68(3):356-63. PubMed ID: 8903478
[TBL] [Abstract][Full Text] [Related]
3. The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts.
Coley HM; Jarman M; Jones M; Sargent JM; Kubota T; Lee NC; Goddard PM; Elgie AW; Williamson C; Taylor CG; Judson IR
Anticancer Res; 1996; 16(4A):1851-5. PubMed ID: 8712712
[TBL] [Abstract][Full Text] [Related]
4. Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
Rutty CJ; Judson IR; Abel G; Goddard PM; Newell DR; Harrap KR
Cancer Chemother Pharmacol; 1986; 17(3):251-8. PubMed ID: 3091280
[TBL] [Abstract][Full Text] [Related]
5. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
[TBL] [Abstract][Full Text] [Related]
6. Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines.
Coley HM; Jarman M; Brooks N; Thornton TJ; Judson IR
Eur J Cancer; 1994; 30A(12):1827-36. PubMed ID: 7880614
[TBL] [Abstract][Full Text] [Related]
7. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies.
Coley HM; Brooks N; Phillips DH; Hewer A; Jenkins TC; Jarman M; Judson IR
Biochem Pharmacol; 1995 May; 49(9):1203-12. PubMed ID: 7763301
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
[TBL] [Abstract][Full Text] [Related]
9. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
Judson IR; Rutty CJ; Abel G; Graham MA
Br J Cancer; 1986 May; 53(5):601-6. PubMed ID: 3087399
[TBL] [Abstract][Full Text] [Related]
10. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
11. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
12. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
Broggini M; Rossi C; Colombo T; D'Incalci M
Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
[TBL] [Abstract][Full Text] [Related]
13. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
14. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
16. Hexamethylmelamine: a critical review of an active drug.
Foster BJ; Harding BJ; Leyland-Jones B; Hoth D
Cancer Treat Rev; 1986 Dec; 13(4):197-217. PubMed ID: 3102057
[TBL] [Abstract][Full Text] [Related]
17. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
19. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.
Cumber AJ; Ross WC
Chem Biol Interact; 1977 Jun; 17(3):349-57. PubMed ID: 407012
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of hexamethylmelamine on human tumor xenografts serially transplanted in nude mice.
Kubota T; Tanino H; Watanabe M; Kitajima M
Anticancer Res; 1994; 14(6B):2521-4. PubMed ID: 7872676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
